PMID- 37944649
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240106
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 894
DP  - 2024 Feb 5
TI  - LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of 
      STAT3.
PG  - 147974
LID - S0378-1119(23)00815-6 [pii]
LID - 10.1016/j.gene.2023.147974 [doi]
AB  - OBJECT: In this study, we aimed to elucidate the role of LUCAT1, a recently 
      identified lncRNA, in ferroptosis within the context of bladder cancer (BC). 
      METHODS: Through a comprehensive array of experimental techniques, including 
      transmission electron microscopy (TEM), RNA pull-down assays, and fluorescence in 
      situ hybridization (FISH), we investigated the molecular interactions and 
      functional consequences associated with LUCAT1 in BC cells. RESULTS: Our findings 
      indicate that LUCAT1 acts as a pivotal regulator in BC, fostering cell 
      proliferation, migration, and invasion, while concurrently impeding ferroptosis. 
      Mechanistically, we unveiled a direct binding between LUCAT1 and insulin-like 
      growth factor 2 mRNA-binding protein 1 (IGF2BP1), which governs the mRNA 
      stability of signal transducer and activator of transcription 3 (STAT3). 
      Intriguingly, ectopic expression of STAT3 counteracted the suppressive effect of 
      LUCAT1 on ferroptosis induction in BC cells. Notably, in an in vivo setting, 
      LUCAT1 emerged as a crucial modulator of ferroptosis inhibition in BC by 
      regulating STAT3 mRNA stability. CONCLUSION: Collectively, our study identifies 
      LUCAT1 as a novel oncogenic player, repressing ferroptosis in BC. These findings 
      shed light on the intricate interplay between lncRNAs and ferroptosis in cancer, 
      implicating LUCAT1 as a promising therapeutic target for patients afflicted with 
      BC. Further investigations into the underlying mechanisms governing 
      LUCAT1-mediated ferroptosis resistance are warranted, with the potential to 
      uncover novel strategies for combating BC progression and improving patient 
      outcomes.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Cao, Yuepeng
AU  - Cao Y
AD  - Department of Colorectal Surgery, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China. Electronic address: MF1535001@smail.nju.edu.cn.
FAU - Zou, Zhuo
AU  - Zou Z
AD  - Graduate School, Dalian Medical University, Dalian, China.
FAU - Wu, Xuhong
AU  - Wu X
AD  - Department of Critical Care Medicine, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China.
FAU - Li, Weijian
AU  - Li W
AD  - Department of Urology, Northern Jiangsu People's Hospital, Clinical Medical 
      College of Yangzhou University, Yangzhou, China.
FAU - Lu, Zhen
AU  - Lu Z
AD  - Department of Anesthesiology, The Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China. Electronic address: luzhen120@Sohu.com.
FAU - Hu, Jiawei
AU  - Hu J
AD  - Department of Endoscopy, The Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Yang, Liu
AU  - Yang L
AD  - Department of Colorectal Surgery, The Affiliated Cancer Hospital of Nanjing 
      Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing, China. Electronic address: yangliu@njmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231107
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (STAT3 protein, human)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (long non-coding RNA LUCAT1, human)
SB  - IM
MH  - Humans
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - *Ferroptosis/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - In Situ Hybridization, Fluorescence
MH  - *MicroRNAs/genetics
MH  - RNA Stability
MH  - *RNA, Long Noncoding/genetics/metabolism
MH  - STAT3 Transcription Factor/genetics/metabolism
MH  - *Urinary Bladder Neoplasms/genetics
OTO - NOTNLM
OT  - Ferroptosis
OT  - IGF2BP1
OT  - LUCAT1
OT  - STAT3
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/11/10 00:44
MHDA- 2024/01/02 11:43
CRDT- 2023/11/09 19:15
PHST- 2023/06/24 00:00 [received]
PHST- 2023/10/29 00:00 [revised]
PHST- 2023/11/06 00:00 [accepted]
PHST- 2024/01/02 11:43 [medline]
PHST- 2023/11/10 00:44 [pubmed]
PHST- 2023/11/09 19:15 [entrez]
AID - S0378-1119(23)00815-6 [pii]
AID - 10.1016/j.gene.2023.147974 [doi]
PST - ppublish
SO  - Gene. 2024 Feb 5;894:147974. doi: 10.1016/j.gene.2023.147974. Epub 2023 Nov 7.